Sutro Biopharma Inc
STRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$295.35M
Close$
$-0.82
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $295.35 Million |
|---|---|
| Enterprise Value | $244.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.49 |
| Beta | 1.55 |
| Outstanding Shares | 130,823 |
Return
| Return on Equity | 229.64% |
|---|---|
| Return on Assets | -63.48% |
| Return on Invested Capital | -68.36% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.2 |
| Price to Sales | 0.04 |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | 2.46 |
| Enterprise Value to EBIT | -2.09 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-2.79
Average shareholder expectationRevenue Estimate
$10.15 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-2.22
Average shareholder expectationRevenue Estimate
$11.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 61,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 164.20%▲ 98.23% |
|---|---|
| Total Invested | $351.11M▲ 441.87% |
| Investors Holding | 72▲ 11.00% |
ESG Score
No data
About Sutro Biopharma Inc
CEO: William Newell